1	Evaluation of Alinity m CMV assay performance for detecting CMV in plasma,			
2	cerebrospinal fluid, and b	ronchoalveolar lavage specimens		
3				
4	Running title: Alinity m CN	IV Assay Performance		
5				
6	Joshua Kostera ¹ , Mark Hub	bard ² , Dillon Jackson ² , Rachael M. Liesman ³		
7				
8	¹ Abbott Molecular, Des Plaines, IL, USA			
9	² Department of Pathology and Laboratory Medicine, The University of Kansas Health			
10	System, Kansas City, KS, USA			
11	³ Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA			
12				
13	Corresponding author:	Rachael Liesman		
14		8701 W Watertown Plank Road, Milwaukee WI 53226		
15		414-805-6972		
16		rliesman@mcw.edu		
17				
18	Word Count			
19	Abstract: 204			
20	Manuscript: 1829			

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 Funding

- 22 This study was funded by Molecular Diagnostics of Abbott.
- 23

24 Conflict of Interest Declaration

- 25 Joshua Kostera is an employee of Abbott Laboratories
- 26 Rachael Liesman has received research support from Abbott Laboratories (reagents,
- 27 supplies)
- 28

29 Abstract

- 30 Introduction: Rapid and accurate detection of cytomegalovirus (CMV) infection and
- 31 reactivation is crucial to preventing adverse outcomes in immunocompromised individuals,
- 32 especially in transplant recipients. Current PCR-based assays were developed for use with
- 33 plasma specimens, but CMV is present in bronchoalveolar lavage fluid (BAL) in
- 34 immunocompromised patients with CMV pneumonia and has also been detected in
- 35 cerebrospinal fluid (CSF).
- 36 **Objectives:** We evaluated the performance of the Abbott Alinity m CMV assay compared to
- 37 the Abbott RealTime CMV assay for quantification of CMV in plasma, BAL, and CSF
- 38 specimens.
- 39 **Methods:** Analytical performance, including linearity, precision, and limit of detection, was
- 40 established for plasma, BAL, and CSF specimen types using reference CMV control material
- 41 (SeraCare). To evaluate clinical performance, 190 plasma specimens, 78 BAL specimens,
- 42 and 26 CSF specimens were tested with the Alinity m assay and compared to the RealTime

43 CMV assay.

- 44 **Results:** The Alinity m CMV assay showed high precision (SD <0.01 to 0.13) within the
- 45 quantifiable range (1.49-8.00 log10 IU/mL) for all 3 specimen types, with strong clinical
- 46 correlation to the RealTime CMV assay results ($r^2=0.9779$ for plasma, $r^2=0.9373$ for BAL,

47 r^2 =0.9889 for CSF).

48 **Conclusion:** The Alinity m CMV assay may be useful for rapid detection of CMV in plasma,

49 BAL, and CSF specimens.

50 Introduction

51 Cytomegalovirus is highly prevalent worldwide(1). After initial infection, CMV becomes latent 52 and can be reactivated in response to stress or suppression of the immune response (2). In 53 immunocompetent individuals, primary CMV infection may be asymptomatic or mildly 54 symptomatic; however, infection or reactivation of latent CMV in immunocompromised 55 individuals is associated with severe to fatal outcomes(2-4). Individuals with hematopoietic 56 stem cell or solid organ transplants are at high risk of graft rejection or loss, multi-organ 57 failure, and death as a consequence of CMV reactivation(5). Ongoing monitoring of CMV 58 DNA load in transplant recipients is therefore essential to prevent CMV-related adverse 59 outcomes(6).

60

61 Highly sensitive and specific nucleic acid amplification tests (NAATs) for quantifying CMV 62 DNA in plasma have been developed for the detection of CMV reactivation and response to anti-CMV treatment(7).CMV can also be detected in bronchoalveolar lavage (BAL) 63 64 specimens from transplant recipients and immunocompromised patients with suspected CMV pneumonia(8-11). CMV infection of the central nervous system may occur in severely 65 66 immunosuppressed patients, such as those with advanced HIV infection, and CMV may be detectable in the cerebrospinal fluid (CSF)(6, 12). Here, we evaluated the performance of 67 the Alinity m CMV assay compared to the Abbott RealTime CMV assay for quantification of 68 CMV viral load in plasma specimens and detection of CMV in CSF and BAL specimens. 69

70

71 Materials and Methods

72 Specimens

Deidentified remnant specimens (plasma, CSF, and BAL) from patients were utilized to
assess the performance of the Alinity m CMV assay. All assays were run in the central
laboratory of a large urban tertiary care hospital. The study was determined to be exempt by
The University of Kansas Health System Institutional Review Board.

77

78 Assay platforms

The Alinity m CMV assay is a real-time PCR-based test that targets regions within the UL34 and UL80.5 genes to detect and quantify CMV DNA in human plasma, with a reported quantitative range of 1.48 to 8.00 log10 IU/mL. The RealTime CMV assay is performed on the *m*2000 platform, consisting of the *m*2000*sp* for sample preparation and *m*2000*rt* for amplification and detection. The RealTime CMV assay assay has the same target region as the Alinity m CMV assay with a quantitative range of 1.70 to 8.19 log10 IU/mL.

85

86 Analytical evaluation

87 To assess limit of detection (LoD) in plasma specimens, the ExactDX (EDX) CMV LoD panel 88 (Exact Diagnostics, Fort Worth, TX) was tested at 1.65 log10 IU/mL and diluted in negative 89 plasma to 1.48 log10 IU/mL; each level was tested in replicates of 20 across 5 days. The 90 LoD was assessed in BAL and CSF by diluting the EDX panel to 2.00, 1.70, and 1.48 log10 91 IU/mL in negative matrix and each level was tested in replicates of 15. The lowest 92 concentration with 100% gualitative detection was determined as the LoD. Precision for 93 plasma specimens was assessed with EDX material at high (5.70 log10 IU/mL) and low (3.0 94 log10 IU/mL) concentrations tested in triplicate daily for 6 days. Linearity for plasma specimens was assessed with the EDX CMV panel, consisting of 6 levels (2.30, 2.60, 3.60, 95 4.60, 5.60, and 6.60 log10 IU/mL) tested in duplicate daily over 4 days. To assess linearity 96 and precision of the Alinity m CMV assay in BAL and CSF specimens, CMV-negative pooled 97 BAL or CSF specimens were spiked with a CMV-positive plasma sample at final 98 99 concentrations of 2.60, 4.60, and 6.60 log10 IU/mL and tested in triplicate daily for 5 days. 100 External Alinity CMV quality control material at high and low concentrations were also tested 101 daily.

102

103 Clinical specimen evaluation

To assess accuracy, a total of 190 deidentified remnant plasma specimens initially tested on
the RealTime CMV assay as part of routine clinical care were tested on the Alinity m CMV

106 assay. Specimens were stored refrigerated (2-8°C) for \leq 48 hours (n=81) or frozen (-20°C; 107 n=109) prior to testing. Additionally, 78 BAL specimens and 26 CSF specimens initially 108 tested using the RealTime CMV assay were tested on the Alinity m CMV assay. Specimens 109 were stored refrigerated (2-8°C) for ≤48 hours (BAL n=14; CSF n=7) or frozen (-20°C; BAL 110 n=64; CSF n=19) prior to testing. Because all clinical CSF specimens were negative for 111 CMV, positive CSF specimens were generated by spiking negative pooled CSF with a 112 known CMV-positive plasma specimen (7.1 log10 IU/mL), which was then serially diluted to 113 the analytical measurement range of 1.6 to 6.6 log 10 IU/mL. The dilutions were tested on 114 both the RealTime CMV assay and Alinity m CMV assay.

115

116 Statistical analysis

117 All analyses were performed using PC SAS (version 9.4) software (SAS, Cary, NC, USA).

118 The percent positive agreement (PPA), negative percent agreement (NPA), and overall

119 percent agreement (OPA) were calculated to determine qualitative method agreement.

120 Variability is expressed as standard deviation (SD) and percent coefficient of variation

121 (%CV). Correlation analysis was performed only on specimens with quantifiable results and

122 was evaluated using by Deming regression analysis and Bland-Altman plots.

123

124 Results

125 Analytical performance

126 The Alinity m CMV assay was determined to be highly reproducible across all 3 specimen

types (Table 1). In plasma, the standard deviation (SD) range was 0.07-0.11, inter-assay

128 coefficients of variation (%CV) ranged from 1.27% to 3.45%, and intra-assay %CV from

- 129 0.84% to 2.32%. In BAL, SD ranged from 0.06-0.13 and inter- and intra-assay %CV ranged
- 130 from 1.38% to 4.74% and 1.17% to 3.76%, respectively. In CSF, SD was below 0.1 and both
- 131 inter- and intra-assay %CVs ranged from 0.71% to 2.12%. The Alinity m CMV assay
- demonstrated excellent linearity in plasma across the quantifiable range (1.49 and 8.00
- 133 log10 IU/mL), consistent with the assay package insert (Figure 1A). Linearity was also

demonstrated in BAL and CSF specimens across the analytical measurement range (Figure
1B and 1C, respectively). The LoD for plasma, BAL, and CSF specimen types was
determined to be 1.48 log10 IU/mL (30 IU/mL) for all matrices. Trend analysis of the high
EQC material from 2 reagent lots by Levey-Jennings plot demonstrated 2 points outside of
±2SD acceptable range and no points oustide of ±3SD acceptable range across 29 nonconsecutive days of testing (Figure 2A). A similar analysis of the low EQC material showed 1
point outside of ±2SD and no points outside of ±3SD acceptable ranges (Figure 2B).

141

142 Clinical performance

143 One hundred and ninety plasma specimens were included in this study and gualitative 144 positive, negative, and overall agreement rates were 95%, 89%, and 93%, respectively 145 (Table 2). Fourteen specimens were discordant, with 8 specimens detected only by the 146 Alinity m assay and 6 specimens detected only by the RealTime assay. All 14 discordant 147 plasma specimens were detected below the limit of quantification of the respective assay 148 (<50 IU/mL for the RealTime assay; <30 IU/mL for the Alinity m assay), consistent with 149 detection variability at the LoD. A total of 97 specimens were within the quantifiable range of 150 both assays and were used to assess clinical correlation between the assays. Deming 151 regression analysis demonstrated high correlation between the 2 assays ($R^2 = 0.9779$; slope 152 = 1.0032) (Figure 3A). A Bland-Atlman plot was used to further analyze correlation between 153 the methods (Figure 3B). Overall bias was -0.06 log10 IU/mL, with only 1 specimen 154 demonstrating a bias >0.5 log10 IU/mL.

155

156 Seventy-eight BAL specimens were assessed for qualitative accuracy, with positive,

negative, and overall agreement rates of 100%, 87%, and 95%, respectively (Table 2). Four

total specimens were discordant, which were detected by the Alinity m assay below the

159 quantifiable range (<30 IU/mL). A total of 40 specimens were within the quantifiable range of

160 both assays. Deming regression analysis showed high correlation between the assays

161 (R²=0.9373; slope 0.9781) (Figure 3C). Bland-Altman analysis demonstrated an overall bias

of -0.28 log10 IU/mL (Figure 3D). Ten specimens (25%) had quantitative values with a bias
>0.5 log10 IU/mL, with 9 specimens resulting in a >0.5 log10 IU/mL higher CMV DNA load
from the RealTime assay and 1 specimen resulting in a >0.5 log10 IU/mL higher CMV DNA
load when tested with the Alinity m assay.

166

167 All negative and contrived positive CSF specimens were concordant between the RealTime

and Alinity m CMV assays (Table 2). For the 6 contrived positive specimens, Deming

regression analysis showed high correlation ($R^2=0.9889$; slope 0.9489) between the 2

170 assays (Figure 3E). Overall bias was -0.20 log10 IU/mL and 1 specimen demonstrated bias

171 >0.5 log10 IU/mL (Figure 3F).

172

173 Discussion

174 In this study, we assessed the analytical performance of the Alinity m CMV assay for

175 quantitation of CMV viral load in plasma, CSF, and BAL specimens as compared to the

176 RealTime CMV assay. Overall, the Alinity m assay demonstrated excellent linearity,

177 precision, and clinical correlation across all 3 specimen types. Additionally, the LoD

178 determined in this study for plasma samples (30 IU/mL) was consistent with the

179 manufacturer's package insert, and an equivalent LoD was also established for BAL and

180 CSF specimens, which were not assessed by the manufacturer.

181

182 Our study findings are consistent with previous studies that have demonstrated the detection

183 of CMV in BAL or bronchial brush specimens with PCR-based tests to diagnose CMV

184 pneumonia in immunocompromised patients, patients with hematologic malignancies, and

185 after transplantation(8, 13, 14). Previous studies have reported difficulty in defining

186 quantitative cut-offs for CMV viral load in BAL specimens associated with CMV

187 pneumonia(10). A recent prospective study identified a CMV load of 831 IU/mL as the

188 diagnostic cut-off for CMV pneumonia; however, the authors recommended NAAT as a

189 complementary test to bronchoscopy for definitive diagnosis(11). Further studies are needed

to establish clinical decision points for CMV viral load values. Although we assessed the
quantitative performance of this assay in CSF and BAL specimens, we report CMV testing
from these specimens qualitatively.

193

194 In our comparative analysis, we found high percent agreement and correlation of results 195 between Alinity m CMV and the RealTime CMV assay for all 3 specimen types. Of 294 total 196 specimens assessed in this study, 18 (6%) were considered discordant. Most discordant 197 samples were detected only by the Alinity m assay (n=12), which may be due to the lower 198 LoD of the Alinity m assay as compared to the RealTime assay. Further, all discordant 199 samples were detected below the limit of quantification, consistent with variable detection of 200 viral DNA at the LoD. Further, no significant bias was demonstrated when comparing plasma 201 specimens tested on both assays, which allows for a change of method without the need for 202 re-baselining of patients. Greater bias was demonstrated when assessing clinical correlation 203 of CMV DNA load in BAL specimens suggesting a potential need for re-baselining patients 204 or reestablishing cut-off values for laboratories reporting quantitative results in BAL 205 specimens.

206

In our single-center study, only a limited number of clinical CSF specimens were available
for testing, and all were found to be negative for CMV. Larger studies are needed to
establish the clinical performance of the Alinity m CMV assay with CSF specimens.

210

In conclusion, we found that the Alinity m CMV assay demonstrated high precision and
accuracy for the quantitation of CMV DNA in both contrived panels and clinical specimens.
The Alinity m platform allows rapid reporting of test results, which may improve turnaround
time allowing for optimized detection and monitoring of CMV in at-risk patients.

215

216 Acknowledgements

- 217 This study was funded by Molecular Diagnostics of Abbott. Stacey Tobin, PhD, provided
- 218 editorial support for manuscript preparation, with compensation from Abbott Laboratories.

219

221 References

- 222 1. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P.
- 223 2019. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic
- review and meta-analysis. Rev Med Virol 29:e2034.
- 225 2. Griffiths P, Baraniak I, Reeves M. 2015. The pathogenesis of human
- cytomegalovirus. J Pathol 235:288-97.
- Boeckh M, Geballe AP. 2011. Cytomegalovirus: pathogen, paradigm, and puzzle. J
 Clin Invest 121:1673-80.
- 4. Camargo JF, Komanduri KV. 2017. Emerging concepts in cytomegalovirus infection
- following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther10:233-238.
- Razonable RR, Humar A. 2019. Cytomegalovirus in solid organ transplant recipients Guidelines of the American Society of Transplantation Infectious Diseases
 Community of Practice. Clin Transplant 33:e13512.
- 235 6. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar
- A, The Transplantation Society International CMVCG. 2018. The Third International
- 237 Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ
- Transplantation. Transplantation 102:900-931.
- 239 7. Razonable RR, Inoue N, Pinninti SG, Boppana SB, Lazzarotto T, Gabrielli L,
- Simonazzi G, Pellett PE, Schmid DS. 2020. Clinical Diagnostic Testing for Human
 Cytomegalovirus Infections. J Infect Dis 221:S74-S85.
- 8. Beam E, Germer JJ, Lahr B, Yao JDC, Limper AH, Binnicker MJ, Razonable RR.
- 243 2018. Cytomegalovirus (CMV) DNA quantification in bronchoalveolar lavage fluid of
 244 immunocompromised patients with CMV pneumonia. Clin Transplant 32.
- 245 9. Boeckh M, Stevens-Ayers T, Travi G, Huang ML, Cheng GS, Xie H, Leisenring W,
- 246 Erard V, Seo S, Kimball L, Corey L, Pergam SA, Jerome KR. 2017. Cytomegalovirus
- 247 (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem
- 248 Cell Transplant Recipients With CMV Pneumonia. J Infect Dis 215:1514-1522.

249	10.	Pinana JL, Gimenez E, Gomez MD, Perez A, Gonzalez EM, Vinuesa V, Hernandez-
250		Boluda JC, Montoro J, Salavert M, Tormo M, Amat P, Moles P, Carretero C,
251		Balaguer-Rosello A, Sanz J, Sanz G, Solano C, Navarro D. 2019. Pulmonary
252		cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell
253		transplant recipients: Implications for the diagnosis of CMV pneumonia. J Infect
254		78:393-401.
255	11.	Saksirisampant G, Kawamatawong T, Promsombat K, Sukkasem W, Liamsombut S,
256		Pasomsub E, Bruminhent J. 2022. A Prospective Study of Plasma and
257		Bronchoalveolar Lavage Fluid CMV DNA Load Quantification for the Diagnosis and
258		Outcome of CMV Pneumonitis in Immunocompromised Hosts. J Clin Virol
259		155:105243.
260	12.	Maschke M, Kastrup O, Diener HC. 2002. CNS manifestations of cytomegalovirus
261		infections: diagnosis and treatment. CNS Drugs 16:303-15.
262	13.	Bewig B, Haacke TC, Tiroke A, Bastian A, Bottcher H, Hirt SW, Rautenberg P,
263		Haverich A. 2000. Detection of CMV pneumonitis after lung transplantation using
264		PCR of DNA from bronchoalveolar lavage cells. Respiration 67:166-72.
265	14.	Lee HY, Rhee CK, Choi JY, Lee HY, Lee JW, Lee DG. 2017. Diagnosis of
266		cytomegalovirus pneumonia by quantitative polymerase chain reaction using
267		bronchial washing fluid from patients with hematologic malignancies. Oncotarget
268		8:39736-39745.

269

270 Figure Legends

- **Figure 1.** Alinity m CMV assay linearity for dilution series in (A) plasma, (B) BAL, and (C)
- 273 CSF.
- 274
- 275 Figure 2. Levey-Jennings plots of (A) high and (B) low external QC. The dashed line
- 276 represents the 2SD acceptable range and the dotted line represents the 3SD acceptable
- 277 range.
- 278
- 279 Figure 3. Comparison of Alinity m CMV and RealTime CMV assay performance in plasma,
- 280 BAL, and CSF. (A) Deming regression of 97 plasma specimens within the quantifiable range
- of both assays and (B) Bland-Altman plot of bias. (C) Deming regression of 40
- 282 bronchoalveolar lavage (BAL) specimens within the quantifiable range of both assays and
- 283 (D) Bland-Altman plot of bias. (E) Deming regression of 6 contrived CSF specimens within
- the quantifiable range of both assays and (F) Bland-Altman plot of bias. The dashed line in
- all Blant-Altman plots represents the average bias.
- 286

Tables 287

	Level (log10 IU/mL)	Mean (log10 IU/mL)	SD (log10 IU/mL)	% <2SD	Inter-assay %CV	Intra-assay %CV
EQC	N/A	5.95	0.08	100	1.31	1.09
	IN/A	3.10	0.09	100	2.91	2.32
Plasma	5.70	5.08 0.05	0.07	100	1.27	0.84
	3.00	3.05	0.11	100	3.45	2.24
	6.60	6.33	0.13	100	2.04	1.32
BAL	4.60	4.59	0.06	100	1.38	1.17
	2.60	2.58	0.12	93	4.74	3.76
	6.60	6.59	0.09	100	1.32	1.02
CSF	4.60	4.81	0.07	93	1.44	0.71
	2.60	2.75	0.06	100	2.12	1.87

288 Table 1. Precision of the Alinity m CMV Assay

BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; CV coefficient of variation; N/A, not 289

available; SD, standard deviation; EQC, external kit quality control material. 290

Table 2. Agreement Between RealTime CMV Assay and Alinity m CMV Assay for Plasma, BAL, and CSF

Placma S	nacimona	RealTi <i>m</i> e		Positivo	Negative Agreement	Overall Agreement
(N=190)		Detected	Not Detected	Agreement		
	Detected	108	8		89%	93%
Alinity m	Not Detected	6	68	95%		
		=		-	-	
RAL Spec	imons	RealTime		Positivo	Negative Agreement	Overall Agreement
(N=78)		Detected	Not Detected	Agreement		
	Detected	48	4		87%	95%
Alinity m	Not Detected	0	26	100%		
					-	
CSE Spor	simons	RealTi <i>m</i> e		Positivo	Negative Agreement	Overall Agreement
(N=26)		Detected	Not Detected	Agreement		
	Detected	6	0		100%	100%
Alinity m	Not Detected	0	20	100%		











